Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MGTX
SELLMeiraGTx Holdings plc · Healthcare · United States · $1.1B · Avg Vol: $13M/d
COMPANY DESCRIPTION
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing and commercializing novel treatments for inherited diseases, with programs in ophthalmology, salivary gland disorders, and Parkinson's disease. The company differentiates itself with its proprietary gene therapy platforms and a vertically integrated approach, including its own GMP manufacturing facility. This strategic integration supports control over its development pipeline for high-unmet-need indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.7M | 15.9M | 14.0M | 33.3M | 81.4M | 21.2% | 79.8M | 49.3M | 95.7M | 8.4% |
| EPS | -1.80 | -2.87 | -1.49 | -2.12 | -1.42 | — | -1.48 | -1.44 | -1.37 | — |
| Shares | 44.5M | 48.5M | 63.6M | 78.4M | 81.1M | +82.1% | 92.6M | — | — | — |
| Debt | 23.7M | 92.2M | 89.3M | 84.8M | 88.7M | 39.0% | 87.5M | — | — | — |
| Equity | 185.4M | 117.7M | 138.2M | 67.8M | -5.8M | -28.5% | — | — | — | — |
| Op CF | -10.5M | -73.1M | -105.4M | -104.5M | -46.4M | — | 8.3M | — | — | — |
| Inv CF | -61.7M | -45.0M | 34.0M | 23.5M | -4.1M | — | — | — | — | — |
| Fin CF | 1.7M | 95.2M | 84.0M | 54.5M | 12.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MGTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MGTX | MeiraGTx Holdings plc(you) | $1.1B | 32 | SELL |
| JBIO | Jade Biosciences, Inc. | $1.2B | 33 | SELL |
| FBRX | Forte Biosciences, Inc. | $1.1B | 28 | SELL |
| ANRO | Alto Neuroscience, Inc. | $940M | 34 | SELL |
| CGEM | Cullinan Therapeutics, Inc. | $1.1B | 37 | HOLD |
| VIR | Vir Biotechnology, Inc. | $1.5B | 32 | SELL |
| NVAX | Novavax, Inc. | $1.2B | 36 | HOLD |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 38 | HOLD |
| XNCR | Xencor, Inc. | $1.4B | 30 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%